Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.
$RXRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2025 | $11.00 | Neutral → Overweight | Analyst |
| 7/3/2025 | $5.00 | Equal-Weight | Morgan Stanley |
| 5/22/2023 | $8.00 | Equal-Weight | Morgan Stanley |
| 3/16/2023 | $17.00 | Buy | Needham |
| 9/16/2022 | $20.00 | Overweight | KeyBanc Capital Markets |
| 4/18/2022 | $10.00 | Buy → Neutral | BofA Securities |
| 3/4/2022 | $32.00 → $10.00 | Outperform → Market Perform | SVB Leerink |
| 12/8/2021 | $30.00 → $32.00 | Outperform | SVB Leerink |
Analyst upgraded Recursion Pharmaceuticals from Neutral to Overweight and set a new price target of $11.00
Morgan Stanley resumed coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $5.00
Morgan Stanley initiated coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $8.00
Salt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in an upcoming investor conference: Goldman Sachs 47th Annual Global Healthcare Conference — Tuesday, June 9, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. About RecursionRecursion (NASDAQ:RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncolog
Salt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 2,991,840 shares of its class A common stock in the aggregate to 33 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the "2024 Plan"). Each award was granted as an inducement material to the employee's commencement of employment with Recursion, or a subsidiary of Recursion, pursuant to Nasdaq Listing Rule 5635(c)(4). Each inducement RSU
SALT LAKE CITY, May 19, 2026 (GLOBE NEWSWIRE) -- Altitude Lab, the platform-first biotech-startup accelerator founded by Recursion (NASDAQ:RXRX), announced today that its portfolio companies have collectively raised more than $205 million in early-stage funding since the program's launch in 2020. The milestone reflects a portfolio of companies advancing into clinical trials, signing deals with global pharma, and commercializing platform technologies reshaping the boundaries of early-stage biotech despite this difficult funding climate. Dr. Joshua Schiffman, CEO/Co-founder of Peel Therapeutics, credits their success to initial support from Altitude Lab, "With Altitude Lab serving as our bi
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
SCHEDULE 13G - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
10-Q - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
Salt Lake City, UT, April 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2026 financial results on Wednesday, May 6, 2026, before the open of the financial markets. Recursion will host an Earnings Call on May 6, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm BST. The company will broadcast the live stream from Recursion's X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFmikcu6. About RecursionR
Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the open of the financial markets. Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFm
Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 financial results on Wednesday, November 5, 2025, before the open of the financial markets.Recursion will host a (L)earnings Call on November 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFmikcu6.About RecursionR
SALT LAKE CITY, May 19, 2026 (GLOBE NEWSWIRE) -- Altitude Lab, the platform-first biotech-startup accelerator founded by Recursion (NASDAQ:RXRX), announced today that its portfolio companies have collectively raised more than $205 million in early-stage funding since the program's launch in 2020. The milestone reflects a portfolio of companies advancing into clinical trials, signing deals with global pharma, and commercializing platform technologies reshaping the boundaries of early-stage biotech despite this difficult funding climate. Dr. Joshua Schiffman, CEO/Co-founder of Peel Therapeutics, credits their success to initial support from Altitude Lab, "With Altitude Lab serving as our bi
Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion's Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a rare and differentiated perspective of how to translate scientific promise into successful clinical programs. Her experience spans executive roles in biotech and large pharma, with p
MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)